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Background: Abdominal aortic aneurysm (AAA) is associated with
peripheral and coronary artery disease (CAD), however little is known about
the prognosis of patients who experienced an acute coronary syndrome (ACS)
and have an AAA. The aim of this study was to assess the prevalence of AAA
in patients hospitalized for ACS and to evaluate it was associated with an
increased cardio-vascular (CV) risk during follow up.
Methods: Between February 1, 2008 and March 30, 2009, patients
admitted for ACS with significant (≥50% stenosis) coronary lesions under-
went echography to check for presence of AAA. The AAA was defined as
dilation of infrarenal aorta with maximum antero-posterior diameter ≥30 mm.
During a 2 years follow-up we recorded all causes death, CV death and non-
fatals CV events. The combination of CV death and CV non-fatals events was
defined as the primary endpoint.
Results: Among 306 patients, 20 AAAs (6,6%) were diagnosed, of
average (±sd) diameter 33±3.7 mm, with a maximum diameter of 45 mm, non
requiring surgery. Follow-up at 2 years was available for 292 patients
(95,7%). During follow-up, 77 patients (25,5%) experienced an event (all
causes death or non-fatals CV event) : 23 deaths (7,6%), of wich 16 were from
CV cause, and 55 non-fatals CV event (18,2%). No event was due to AAA.
In univariate analysis age, abdominal aortic diameter, diabetes mellitus, previ-
ously known CAD and AAA were significantly associated with fatal and non-
fatal CV event (p<0,05). In multivariate analysis, age (OR=1.03; 95%CI
(1.008,1.058), diabetes mellitus (OR=1.7; 95%CI (1.05,2.7) and AAA
(OR=3.2; 95%CI (1.24,8.44) were independantly associated with the risk of
fatal or non-fatal CV event. Age (OR=1.18 95%CI (1.10,1.26) and AAA
(OR=4.17 95%CI (1.17,14.9) were the only independant predictors of all
causes death.
Conclusion: Our results show that in patients with CAD, the presence of
small non surgical AAA is associated with worse CV prognosis and higher all
causes mortality at 2 years.
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Background: Type 2 endoleaks after endovascular aortic repair (EVAR)
still represent a problematic issue for vascular surgeon to stop the aneurysmal
degeneration of the unsuccessfully excluded aneurysm. This study was
designed to assess the efficacy of secondary interventions performed on
continuing expanding abdominal aortic aneurysms (AAA) after EVAR with an
identified type 2 endoleak.
Methods: We retrospectively reviewed patients treated by EVAR for
AAA, in which follow-up data of more than 1 year were available. Endoleak
incidences, sac diameters, and secondary procedures were collected. Patients
with type 2 endoleaks and continuing expanding AAA were identified. Pri-
mary endpoint was the efficacy of these reinterventions on the postoperative
AAA diameter course. Secondary endpoints were the aneurysm-related mor-
bidity and mortality, and the cost effectiveness of these complementary proce-
dures.
Results: Out of 232 reviewed patients treated by EVAR for AAA, with a
mean follow-up of 3 years (37±30 months), 15 type 1 (6.5%), 94 type 2
(40.5%), and 8 type 3 (3.5%) endoleaks were identified. Among the 94 AAA
with a type 2 endoleak, 21 presented a sac regression (22.5%), 46 were stable
(49.5%), and 27 presented a sac enlargement (28%). Eight of these last sub-
group of patients had another type of endoleak associated that required partic-
ular treatments. Among the 19 patients presenting a type II endoleak
responsible for sac enlargement, 15 were indicated for embolisation proce-
dures, 1 was treated by immediate open repair, and 3 are still under surveil-
lance. Among the 15 patients treated by embolisation, 9 (60%) had still an
aortic sac enlargement postoperatively, requiring finally 6 open repairs with
one postoperative death. The mean extra cost by patient induced by secondary
procedures for type 2 endoleak was 27110±3098 Euros.
Conclusion: In our experience, endovascular reinterventions for type 2
endoleaks associated with an aortic sac enlargement after EVAR have a poor
efficiency on the stabilization of AAA diameter. These procedures entail extra
costs and morbidity that should be taken into account in their indication.
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Background: Troponin elevation in the setting of acute pulmonary embo-
lism (PE) is of small magnitude and short duration and can go unnoticed in
pts referred late after symptom onset.
Methods: Prospective, single-center registry of pts with confirmed inter-
mediate-risk PE, defined as at least 1 echocardiographic finding of right ven-
tricular (RV) dysfunction (endo-diastolic (EDRV)/left ventricular (EDLV)
end-diastolic diameter ratio >=1 in the 4-chamber view, paradoxical septal
systolic motion or pulmonary hypertension defined as RV/atrial gradient
>30mmHg), or positive troponin test. Combined in-hospital endpoint was
defined as death, non-fatal recurrent PE, or residual pulmonary vascular
obstruction (RPVO) ≥35%.
Results: 282 pts were included, age 66±14 years, 59% women, 174 (62%)
referred ≤5 days after symptom onset, 108 (38%) after >5 days. Troponin ele-
vation was observed in 126 (72%) treated within ≤5 days, in 60 (56%) treated
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